[Clinical and laboratory experience in the treatment of epilepsy with barbexaclone. Considerations on 29 cases].
Twenty nine patients were treated with barbexaclone for 6-41 months. Eighteen of these patients suffered from grand-mal epilepsy and complete control of the crises was achieved in 16 of them. No alterations were noted in the hemogram, liver or renal function tests. Side effects were minimal and didn't necessitate discontinuing the drug. 25% of the patients also showed a psychological improvement on the medication.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011437:Propylamines / Q000031:analogs & derivatives / Q000627:therapeutic use
D011437:Propylamines; C011019:barbexaclone; D010634:Phenobarbital
Experiência clínica e laboratorial no tratamento da epilepsia com barbexaclone. Consideraçoes sobre 29 casos.